IVA337

DRUG3 trials

Sponsors

Inventiva Pharma

Conditions

Diffuse Cutaneous Systemic SclerosisNASH - Nonalcoholic SteatohepatitisNon-Alcoholic Steatohepatitis (NASH)Scleroderma, Diffuse

Phase 2

Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis

CompletedNCT02503644

Inventiva PharmaDiffuse Cutaneous Systemic Sclerosis, Scleroderma, Diffuse

Start: 2015-10-29End: 2018-10-12Updated: 2019-03-04

Phase 2b Study in NASH to Assess IVA337

CompletedNCT03008070

Inventiva PharmaNon-Alcoholic Steatohepatitis (NASH)

Start: 2017-02-07End: 2020-03-16Updated: 2023-07-19

Phase 3

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

Active, not recruitingNCT04849728

Inventiva PharmaNASH - Nonalcoholic Steatohepatitis

Start: 2021-08-19End: 2027-09-30Target: 1000Updated: 2026-07-02

Related Papers

Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials.

2026-03-31

Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis.

2025-03-171 citations

The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis.

2024-05-1038 citations

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

New England Journal of Medicine2021-10-20646 citations

A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.

2020-10-0856 citations